Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 156-162, June 2010

Primary cutaneous marginal zone lymphoma

  • Stéphane Dalle

      Affiliations

    • Service de dermatologie, Université Claude Bernard Lyon I, Hospices Civils de Lyon, Lyon, France
    • Corresponding Author InformationCorresponding author at: Service de Dermatologie, Centre Hospitalier Lyon-Sud, 165 chemin du grand Revoyet, 69495 Pierre Bénite, France. Tel.: +33 478920936; fax: +33 478920939.
  • ,
  • Luc Thomas

      Affiliations

    • Service de dermatologie, Université Claude Bernard Lyon I, Hospices Civils de Lyon, Lyon, France
  • ,
  • Brigitte Balme

      Affiliations

    • Service de dermatologie, Université Claude Bernard Lyon I, Hospices Civils de Lyon, Lyon, France
  • ,
  • Charles Dumontet

      Affiliations

    • Hématologie, Université Claude Bernard Lyon I, Hospices Civils de Lyon, Lyon, France
  • ,
  • Catherine Thieblemont

      Affiliations

    • Service d’hémato-oncologie, Hôpital Saint-Louis, Université Paris Diderot 7, Institut Universitaire d’Hématologie, Paris, France

Accepted 16 September 2009. published online 12 October 2009.

Abstract 

Primary cutaneous marginal zone B-cell lymphoma (PCMZL) is included in the group of extranodal marginal zone B-cell lymphoma involving mucosal sites. Many evidences suggest that chronic antigen stimulation is a key-player in its pathogenesis. While Helicobacter pylori seems not to be implicated in PCMZL, Borrelia Burgdorferi's role is still matter of debate since the results are discordant between European and North American/Asian countries. However Borrelia subspecies are different between the studied areas and this difference could be a confounding factor. Then ubiquitous candidate antigen is still missing. Beyond these discrepancies the treatment of diffuse PCMZL has been recently improved. If local therapies (surgery, radiation) are the gold standard for localized disease, rituximab can also be considered as an alternative for disseminated or plurifocal PCMZL.

Keywords: Cutaneous lymphoma, Marginal zone lymphoma, Rituximab, Review

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1040-8428(09)00180-2

doi:10.1016/j.critrevonc.2009.09.003

Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 156-162, June 2010